The Use of Microporous Polysaccharide Hemospheres in Thyroid Surgery: A Retrospective Study on Safety and Clinical...

Background and Objectives: Hemostasis during thyroid surgery is crucial to avoid postoperative complications, particularly hematoma, which can cause life-threatening airway compromise. Arista™ AH, a plant-based absorbable hemostatic powder, is designed to enhance intraoperative bleeding control. The present study evaluates the efficacy and safety of Arista™ AH in thyroidectomy. Materials and Methods: This retrospective study included 102 patients who underwent thyroidectomy between January 2020 and February 2024. Of these, 63 patients (61.8%) received Arista™ AH as an adjunctive hemostatic agent, and 39 (38.2%) underwent only conventional hemostasis. Outcomes measured included the incidence of postoperative hematoma and seroma, adverse events related to the use of Arista™ AH, and length of hospital stay. Results: None of the patients in the Arista™ AH group developed a hematoma in the thyroid surgical bed, whereas this complication occurred in 2 patients (5.1%) of the control group (p = 0.07). No patients in the Arista™ AH group developed a postoperative seroma, compared with 2 patients (5.1%) in the control group (p = 0.07). No adverse events related to Arista™ AH were reported. Length of hospital stay was similar between groups, with a median of 2 days (IQR 1) in both the Arista™ AH and control groups (p = 0.8). Conclusions: Arista™ AH was associated with favorable postoperative outcomes in thyroid surgery, supporting its safe and effective use as a hemostatic adjunct.